TICKERNERD
Menu
NIKINIKIHealthcare · Biotechnology

NIKI Stock Forecast: Niki Biosolutions, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$1.77
−9.51% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 10 of 100 as at 31 Oct 2026 — in the weakest quartile.

Market cap
$5.5M
Ticker Nerd rank
10/ 100
Median analyst target
—
Analysts covering
0
Revenue$0.0
Operating income−$825K
Net income−$311K
Free cash flow−$536K
Quarterly, 8 quarters to 31 Dec 2025 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.3%
1M
−63.9%
YTD
−83.3%
1Y
−88.0%
From 52W high
−89.1%
From 52W low
0.0%
$2
$16
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NIKI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Niki Biosolutions, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
10/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
94
Growth
63
Accruals
31
Revisions
25
Volatility
23
Issuance
22
Quality
13
Momentum
5
Value
3

Size (94): Smaller than most of the companies we track.

Value (3): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

NIKI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NIKI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15Jan 26Apr 26Jul 26Oct 26NIKI

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first
DateFirmActionRatingTarget
7 Oct 2022HC Wainwright & Co.InitiatesBuy$8.00
2 Apr 2019China RenaissanceInitiatesBuy$22

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

NIKI appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

NIKI vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, Niki Biosolutions, Inc. returned −88.0% against +12.4% for the S&P 500, dividends included.

NIKI vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26NIKIS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NIKI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Niki Biosolutions, Inc. (NIKI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
2.8×

Cheaper than 68% of US stocks

Price / sales
—
Price / book
0.1×

Cheaper than 90% of US stocks

EV / EBITDA
2.6×

Cheaper than 56% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−17.1%

Higher than 33% of US stocks

Return on assets
−10.0%

Higher than 26% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Niki Biosolutions, Inc. (NIKI) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Niki Biosolutions, Inc. has a market value of $5.5M and an enterprise value of −$6.2M.

  • Revenue in the twelve months to 31 Dec 2025: $0.0.

  • Net income over the same four quarters: −$2.4M.

  • Free cash flow in the twelve months to 31 Dec 2025: −$929K.

  • Shares outstanding: 814,375.

  • Trailing P/E: 2.8×; forward P/E: −1.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Niki Biosolutions, Inc. employs 1 people.

Statement figures: company filings via Twelve Data, four quarters to 31 Dec 2025 · market figures as at 1 Nov 2026

Data provided by Twelve Data

Peers

NIKI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
NIKINiki Biosolutions, Inc.$5.5M10
SKYESkye Bioscience, Inc.$5.7M40
LGVNLongeveron, Inc.$5.3M35
PCSAProcessa Pharmaceuticals, Inc.$5.3M24
ACXPAcurx Pharmaceuticals, Inc.$5.8M25
ALZNAlzamend Neuro, Inc.$5.8M27
SNTISenti Biosciences Holdings, Inc.$5.1M42

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Niki Biosolutions, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NIKI news & analysis

Niki BioSolutions Announces New York State Approval for Its APOE Genotyping Test Using Dried Blood Spots, Plasma, and Urine

GlobeNewsWire · 26 Oct 2026positive

Niki BioSolutions announced New York State approval for its APOE genotyping test using dried blood spots, plasma, and urine. The approval extends its validated test beyond blood, buccal swab, saliva, and tissue for clinical and research use.

Why it matters — NIKI watchers may note the expanded range of sample types approved for the company’s APOE genotyping test.

Niki BioSolutions Signs Agreement to Supply APOE Genotyping to Charter Research

GlobeNewsWire · 23 Oct 2026positive

DiamiR Biosciences, Niki BioSolutions’ wholly owned subsidiary, signed an agreement to perform APOE genotyping for Charter Research, a multi-site clinical research organization conducting Alzheimer’s and other clinical trials. The agreement brings the company’s CAP- and NYS CLEP-approved test to Charter Research’s network.

Why it matters — The agreement adds a multi-site clinical research organization as a customer for Niki BioSolutions’ subsidiary’s APOE genotyping service.

Niki BioSolutions' Rett Syndrome Biomarker Program Featured in the International Rett Syndrome Foundation's “Rett Research Tool Belt” Series

GlobeNewsWire · 16 Oct 2026positive

Niki BioSolutions' blood-based microRNA biomarker panel for Rett syndrome was featured in the International Rett Syndrome Foundation's “Rett Research Tool Belt” series. The panel is designed to support monitoring disease progression and treatment response.

Why it matters — The feature highlights Niki BioSolutions' Rett syndrome biomarker program and its intended monitoring applications.

Niki BioSolutions Partners with Global Alzheimer's Platform Foundation to Deliver Plasma-Based APOE Genotyping for Bio-Hermes-002

GlobeNewsWire · 14 Oct 2026positive

Niki BioSolutions is partnering with the Global Alzheimer’s Platform Foundation to provide plasma-based APOE genotyping for Bio-Hermes-002. The testing will add genetic risk data to a diverse, deeply characterized Alzheimer’s biomarker cohort.

Why it matters — The partnership connects NIKI’s plasma-based genotyping services with an Alzheimer’s research cohort.

Niki BioSolutions to Participate in the Lytham Partners Fall 2026 Investor Conference

GlobeNewsWire · 25 Sept 2026neutral

Niki BioSolutions announced it will participate in the Lytham Partners Fall 2026 Investor Conference, which is being held virtually on September 29-30, 2026. The company will deliver a webcast presentation and host one-on-one meetings with investors at the conference.

Why it matters — The investor conference participation offers NIKI watchers an opportunity to hear directly from management and engage with the company during one-on-one investor meetings.

FAQ

Frequently asked questions about NIKI stock

How does Ticker Nerd's model rank NIKI?

As at 31 Oct 2026, Niki Biosolutions, Inc. ranks 10 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (94 of 100).

What is the NIKI stock forecast for 2030?

No analyst covering Niki Biosolutions, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NIKI are extrapolating price history, which says nothing about the business.

How has NIKI stock performed over the past year?

Niki Biosolutions, Inc. returned -88.0% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Niki Biosolutions, Inc. do?

Niki BioSolutions, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutic products for oncology and infectious diseases.

What is the latest news on NIKI?

The most recent item we track (GlobeNewsWire, 26 Oct 2026): "Niki BioSolutions Announces New York State Approval for Its APOE Genotyping Test Using Dried Blood Spots, Plasma, and Urine". Niki BioSolutions announced New York State approval for its APOE genotyping test using dried blood spots, plasma, and urine. The approval extends its validated test beyond blood, buccal swab, saliva, and tissue for clinical and research use.

Company

About Niki Biosolutions, Inc.

Niki BioSolutions, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutic products for oncology and infectious diseases. Its current pipeline includes repurposed drug candidates and small molecules under clinical and preclinical evaluation, with programs aimed at treating neuroblastoma, bacterial infections, and coronavirus disease. The company also works on additional therapeutic assets targeting unmet medical needs across cancer and infectious disease areas. Based in Princeton, New Jersey, Niki BioSolutions operates through subsidiaries and maintains a product portfolio centered on drug development and translational research. Its role in the financial market reflects that of a specialized biotechnology issuer tied to early-stage clinical progress and pipeline advancement.

CEO Mr. Chung Yuen Huen · 1 employees · United States · https://www.aptorumgroup.com